Pfizer in cancer vaccine pact with Avant

Avant Immunotherapeutics stands to receive at least $50 million from an agreement with Pfizer for the development of CDX-110, an experimental brain cancer vaccine. The drugmakers plan to test CDX-110 -- acquired by Avant after finalizing a merger with Celldex Therapeutics -- for other cancers, including breast, ovarian, advanced prostate and colorectal cancer.

View Full Article in:

American City Business Journals · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC